Vir Biotechnology (NASDAQ:VIR) has in-licensed non-exclusive rights to Xencor’s (NASDAQ:XNCR)
Xtend Fc technology aimed at extending the half-lives of novel
antibodies it is investigating for the potential treatment of COVID-19.
Under the terms of the agreement, Vir will be
responsible for all R&D, regulatory and commercial activities.
Specific financial terms are not disclosed.
Xencor’s Xtend XmAb Fc domains increase
circulating half-life by increasing binding affinity to a receptor
called FcRn which is present inside lysosomes in epithelial cells lining
blood vessels. They “rescue” antibodies from the degradation that make
most proteins short-lived in circulation.
https://seekingalpha.com/news/3555208-vir-inks-deal-xencor-for-antibody-extending-technology
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.